Henrik Zetterberg

With a background in molecular biology and clinical chemistry, I have spent the last 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. My research is translational and the biomarkers are evaluated in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. I have developed new diagnostic tests for Alzheimer’s disease, as well as new preclinical models, and have shown that amyloid pathology precedes tau pathology with around 5 years during the Alzheimer disease process in humans, that altered amyloid homeostasis in the brain is evident already in pre-symptomatic stages of the disease, and that the diagnostic usefulness of AD biomarkers decreases with age due to increased prevalence of preclinical Alzheimer neuropathology.